Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based healthcare company Abbott Laboratories has received a complete response letter from the FDA for its new drug application for a controlled-release form of hydrocodone with acetaminophen.
Subscribe to our email newsletter
Abbott is evaluating the FDA complete response letter. The company said that it will discuss the letter with the FDA and will provide an update when appropriate.
Abbott is seeking the approval of controlled-release hydrocodone with acetaminophen as the first extended release medication in the class to provide extended relief over 12 hours; currently available short-acting hydrocodone and acetaminophen medications must be taken every four to six hours.